Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

Katrina L. Ellis, Gerald F. Watts

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Lipoprotein (a) is a low-density lipoprotein-like particle covalently bound to a glycoprotein called apolipoprotein(a) that is under potent genetic control. Plasma levels of lipoprotein (a) vary by up to 1000-fold among individuals, with 1 in 4 having levels that increase the risk of atherosclerotic cardiovascular disease. New evidence supports a causal role for lipoprotein (a) in atherosclerotic cardiovascular disease and aortic valve stenosis. Individuals with elevated lipoprotein (a) have a high life-time burden of atherosclerotic cardiovascular disease. This notion is important for coronary prevention. But is lipoprotein (a) ready for prime-time use in coronary prevention clinics?

Original languageEnglish
Pages (from-to)287-298
Number of pages12
JournalCardiology Clinics
Issue number2
Publication statusPublished - 1 May 2018


Dive into the research topics of 'Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?'. Together they form a unique fingerprint.

Cite this